From Yahoo MB-Updated Cytosorbents Overview
- CytoSorb is a first-in-class extracorporeal cytokine adsorber that CE Mark approved for sale in the European Union and non-EU countries that honor the CE Mark
- The Cytosorb filter consists of pourus polymer beads the size of a grain of salt. The effective surface area of the beads is equivalent to 5 football fields. The pores are engineered to adsorb pro-inflammatory cytokines with a molecular mass in the range of 10-50 Kilo-Daltons. The filter cartridges fit in standard dialysis machines and Cardiopulmonary bypass pumps
- Technology that is protected by 32 issued U.S. patents
- Conditions or procedures resulting in elevated cytokines that could benefit from Cytosorb treatment include: sepsis, burn injury, trauma, lung injury, cardiac surgery, cancer cachexia, pancreatitis, liver failure, rhabdomyolysis and other inflammatory conditions
- DARPA and SBIR contracts
- U.S. Air Force funded 30-patient randomized controlled human pilot study in trauma and rhabdomyolysis
- On track to submit an IDE application to the FDA to run a pivotal trial for the use of Cytosorb in cardiac surgery, and hopefully will submit by the end of 2014 and begin the trial next year
- Austrian cardiac surgery trial results expected soon
- Results of a Cytosorb German multi-center dosing study may be available soon
- 40+ investigator initiated studies being planned with many enrolling
- Support of 150+ Key Opinion Leaders
- CytoSorb is being marketed in 28 countries worldwide
- Partnership with Fresenius
- Partnership with Biocon
- Partnership with LINC Medical
- Partnership with a to be named top 4 cardiac surgery company
- Exclusive distribution agreement with Hemoscien Corporation in Taiwan
- Exclusive agreement with Techno Orbits in the Middle East, including Saudi Arabia, the United Arab
Emirates, Kuwait, Qatar, Bahrain, and Oman (the Gulf Cooperation Council or GCC) and Yemen, Iraq, and Jordan
- Established a world class Cardiac Surgery Advisory Board
- Launched the International CytoSorb Registry
- Posted its fifth consecutive quarter of double-digit quarter-over-quarter growth
- Hemodefend, another possible eventual multi-billion dollar product
- Results of the ABLE study expected soon, that may potentially reinforce the need for a product like
Hemodefend
- Up listing to Nasdaq capital markets in a few days with expected institutional buying interest
- Proud sponsor of the Global Sepsis Alliance (annual World Sepsis Day and Celebration of Sepsis Heroes).
- Collaboration with University of Pennsylvania Vet School to expand Cytosorb Research in cancer immunotherapy
- Cytosorbents was awarded the Beacon of Light Award in 2014
- Cytosorbents was the Health sector winner at the 2014 GREAT Tech Awards
- U.S. House of Representatives Rush Holt awarded CytoSorbents an Export Achievement Award from the U.S.
Department of Commerce and the International Trade Administration
- Sponsored a research symposium entitled: "SIRS and SEPSIS – New Therapy with CytoSorb®"at the 34th
International Symposium on Intensive Care and Emergency Medicine (ISICEM 2014) in Brussels, Belgium
- Etc…
